Eikon Therapeutics is a late-stage clinical biopharmaceutical company focused entirely on developing oncology drugs, with no approved products and no product revenue. Eikon's pipeline spans four programs across three biological themes. Its lead program, EIK1001, is a systemically administered TLR 7/8 dual-agonist designed to activate the immune system against tumors. It is being developed in combination with Merck's pembrolizumab for advanced melanoma and non-small cell lung cancer, with Phase 2/3 registrational trials underway or in site selection. Eikon in-licensed EIK1001 from Seven and Eight Biotherapeutics in 2023. Its second program involves two selective PARP1 inhibitors — EIK1003 and EIK1004 — targeting cancers with DNA repair deficiencies; EIK1004 adds the ability to cross the blood-brain barrier for brain metastases. These were in-licensed from Impact Therapeutics. Eikon also has two internally developed candidates: EIK1005, a WRN helicase inhibitor targeting MSI-high tumors in Phase 1/2, and EIK1006, an androgen receptor antagonist for drug-resistant prostate cancer in preclinical studies. Internal discovery is powered by Eikon's proprietary Single Molecule Tracking platform, which observes individual protein behavior in living human cells using custom super-resolution microscopy and AI-driven data processing. Eikon funds operations through capital markets, burns cash across its roughly 380-person workforce, and plans to commercialize drugs directly or via partners upon potential FDA approval.